- |||||||||| ezogabine (XEN496) / Xenon, Humira (adalimumab) / AbbVie
Journal, Adverse events: Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024. (Pubmed Central) - Sep 14, 2024 Additionally, less commonly associated drugs, such as adalimumab and others, were implicated, suggesting potential under-recognition of this adverse effect...This study underscores the importance of pharmacovigilance in identifying and understanding DIUR. Further research is needed to confirm these findings and develop strategies to manage and reduce the risk, improving patient outcomes.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: ADALIMUMAB DRUG MONITORING AND TREATMENT ADJUSTMENT TO DRUG ANTIBODIES IN NON-INFECTIOUS UVEITIS. (Pubmed Central) - Sep 14, 2024 This underscores immunogenicity as a major cause of loss of response in uveitis patients receiving biotherapies. Increasing the dose of adalimumab injections together with the addition of low-dose cDMARDs was the most effective adjustment in immunized non-responders for whom the adalimumab drug concentration was low.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Review, Journal: Current Practices and Emerging Therapies to Optimize Heart Failure Management in Cardiac Sarcoidosis: A Systematic Review. (Pubmed Central) - Sep 10, 2024 Immunosuppressive agents like methotrexate and azathioprine are used to avoid long-term steroid use...Biological agents like infliximab and adalimumab prevent disease progression by targeting specific inflammatory pathways and are used in refractory cases...Due to a lack of standard protocols for management and limited knowledge about CS, the ideal treatment of HF is still a matter of debate. Hence, further research and clinical trials need to be performed to optimize patient outcomes.
- |||||||||| tofacitinib / Generic mfg.
Journal: Remission of refractory esophageal lichen planus induced by tofacitinib. (Pubmed Central) - Sep 9, 2024 The initiation of the JAK inhibitor tofacitinib induced an impressive clinical, endoscopic, and histological remission. This positive response to a JAK inhibitor is discussed in the context of our evolving understanding of the immune-mediated pathogenesis of this disease.
- |||||||||| Review, Journal: Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. (Pubmed Central) - Sep 1, 2024
Due to the potential significant impairment in quality of life caused by pouchitis, it is essential to address the gaps in knowledge for both patients and physicians in its treatment. Therefore, well-designed and adequately powered studies should assess the optimal treatment for pouchitis.
- |||||||||| Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. (Pubmed Central) - Sep 1, 2024
agent, as reported by 2 studies...Safety was comparable across therapies. Future studies should explore the literature gaps identified, including limited comparative studies with small sample sizes, variations in study designs and patient characteristics, varied definitions of CR, and limited use of patient-reported outcome measures in real-world settings.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Case 328: Brown Tumor in Hyperparathyroidism Due to Parathyroid Adenoma. (Pubmed Central) - Aug 27, 2024 inhibitor (adalimumab), which was effective for pain, the patient was lost to follow-up...Routine blood tests revealed a normal blood cell count, creatinine level of 0.64 mg/dL (56.58 ?mol/L) (normal range, 0.30-1.1 mg/dL [26.52-97.24 ?mol/L]), C-reactive protein level of 1.1 mg/dL (normal, <1 mg/dL), and vitamin D level of 21 ng/mL (52.42 nmol/L) (normal range, 30-100 ng/mL [74.88-249.60 nmol/L]). Noncontrast MRI of the thoracic and lumbar spine, MRI of the sacroiliac joints, and CT of the abdomen and pelvis were performed.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Treatment of facial and axillary lupus miliaris with adalimumab. (Pubmed Central) - Aug 26, 2024 Furthermore, the preliminary results related to the molecular mechanisms of NET formation in JIA patients provide a theoretical basis for NET-targeted therapy. No abstract available
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Journal: Clinical and Ultrasonographic Remission in Bio-na (Pubmed Central) - Aug 23, 2024 UPARAREMUS is the first study evaluating the efficacy of upadacitinib in reaching both clinical and US remission in patients with RA. At 24
- |||||||||| Review, Journal: Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors (Pubmed Central) - Aug 23, 2024
Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Review, Journal: Pyodermatitis-pyostomatitis vegetans: a case report and systematic review focusing on oral involvement. (Pubmed Central) - Aug 17, 2024 There is no established therapeutic protocol for PSV and management primarily consists of topical and/or systemic corticosteroids, antirheumatic drugs (sulfasalazine, mesalazine), monoclonal antibody (infliximab, adalimumab) immunosuppressives (azathioprine, methotrexate), antibiotics (dapsone), or a combination of these. The risk of recurrence of oral lesions is considerable when the medication dose is decreased or fully interrupted.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Treatment Persistence Among Advanced Therapy-Na (Pubmed Central) - Aug 14, 2024 Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy. This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-na
|